TGA provisional approval brings first targeted treatment for SOD1 linked ALS to Australia

June 1, 2026 Latest News BioPharma

This is a preview of subscriber content

Subscribe now to continue reading.

Alice Tien, Managing Director of Biogen Australia and New Zealand, said, “People living with ALS and those who support them have waited a long time to see meaningful progress against this devastating disease." …

Subscribe now to continue reading.

Latest Video

Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - Latest News
Opportunity #4 - Scope creep demands stronger checks and balances
August 19, 2026 - Latest News
Departmental restructure formally splits medicines financing from pharmacy services
August 19, 2026 - Latest News
CSL absorbs loss in reset year as investors back its plasma-led recovery
August 18, 2026 - Latest News
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - Latest News

TGA provisional approval brings first targeted treatment for SOD1 linked ALS to Australia

This is a preview of subscriber content

Latest Video

Most Read

Opportunity #1 - biosimilar policy failure has become impossible to ignore

Opportunity #4 - Scope creep demands stronger checks and balances

Departmental restructure formally splits medicines financing from pharmacy services

CSL absorbs loss in reset year as investors back its plasma-led recovery

Opportunity #2 - AI can democratise HTA and the negotiations must not squander it

New Stories

Advent moves to acquire majority stake in NZCR Group

Personalised mRNA cancer therapy clears Phase 3 milestone in resected melanoma

Biogen bolsters leadership ranks as it sharpens focus on patient access and innovation

Opportunity #5 - From the hardest thing to secure to the easiest thing to get right

Rare autoimmune diseases impose a $1.2 billion annual burden on Australians

New Zealand researchers honoured for work tackling superbugs and blood cancer

Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm

Sign In

TGA provisional approval brings first targeted treatment for SOD1 linked ALS to Australia

This is a preview of subscriber content

Latest Video

Most Read

Opportunity #1 - biosimilar policy failure has become impossible to ignore

Opportunity #4 - Scope creep demands stronger checks and balances

Departmental restructure formally splits medicines financing from pharmacy services

CSL absorbs loss in reset year as investors back its plasma-led recovery

Opportunity #2 - AI can democratise HTA and the negotiations must not squander it

Follow Us

New Stories

Advent moves to acquire majority stake in NZCR Group

Personalised mRNA cancer therapy clears Phase 3 milestone in resected melanoma

Biogen bolsters leadership ranks as it sharpens focus on patient access and innovation

Opportunity #5 - From the hardest thing to secure to the easiest thing to get right

Rare autoimmune diseases impose a $1.2 billion annual burden on Australians

New Zealand researchers honoured for work tackling superbugs and blood cancer

Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm